Lipid-lowering agents and new onset diabetes mellitus

Bibliography

• Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Allen J, Blair SN, AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006;47:2130-9
   PubMed Web of Science ®Google Scholar
• Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-414
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008;24:1359-62
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006;7:211-28
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Norrie J, Sattar N, Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, ; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
   PubMed Web of Science ®Google Scholar
• Prasad GVR, Kim SJ, Huang M, Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methyglutaryl-coenzyme A reductase inhibitors (statins). Am J Transplant 2004;4:1897-903
   PubMedGoogle Scholar
• Krentz AJ, Wheeler DC. New-onset diabetes after transplantation: a threat to graft and patient survival. Lancet 2005;365:640-42
   PubMedGoogle Scholar
• Holdaas H, Fellström B, Jardine AG, Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
   PubMed Web of Science ®Google Scholar
• Rajpathak SN, Kumbhani DJ, Crandall J, Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924-9
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010. [Epub ahead of print]
   Google Scholar
• Cannon CP. Balancing the benefits of statins versus a new risk-diabetes. Lancet 2010. [Epub ahead of print]
   Google Scholar
• Kjekshus J, Apetrei E, Barrios V, Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Julius S, Mancia G, Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006;24:1405-12
   PubMed Web of Science ®Google Scholar
• Aksnes TA, Kjeldsen SE, Rostrup M, Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial population. Hypertension 2007;50:467-73
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F, Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
   PubMed Web of Science ®Google Scholar
• Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107
   PubMed Web of Science ®Google Scholar
• Kaya C, Pabuccu R, Cengiz SD, Dünder I. Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study. Exp Clin Endocrinol Diabetes 2010. [Epub ahead of print]
   Google Scholar
• Koh KK, Quon MJ, Han SH, Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008;31:776-82
   PubMed Web of Science ®Google Scholar
• Koh KK, Quon MJ, Han SH, Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009;204:483-90
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Lagos KG, Baseline triglyceride levels in insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol 2008;590:327-32
   PubMed Web of Science ®Google Scholar
• Goldstein MR, Mascitelli L, Pezzetta F. Statin therapy, muscle function and vitamin D. QJM 2009;102:890-1
   PubMedGoogle Scholar
• Adit A, Ginde AA, Liu MC, Camargo CA Jr. Demographic Differences and Trends of Vitamin D Insufficiency in the US Population, 1988-2004. Arch Intern Med 2009;169:626-32
   PubMedGoogle Scholar
• Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 2007;85:860-8
   PubMed Web of Science ®Google Scholar
• Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia 2005;48:1247-57
   PubMed Web of Science ®Google Scholar
• Laaksonen MA, Knekt P, Rissanen H, The relative importance of modifiable potential risk factors of type 2 diabetes: a meta-analysis of two cohorts. Eur J Epidemiol 2010;25:115-24
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Athyros VG, Adamidou F, Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk? Curr Vasc Pharmacol 2010. [Epub ahead of print]
   Google Scholar
• Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 2008;10:185-97
   PubMed Web of Science ®Google Scholar
• Scragg R, Sowers M, Bell C; Third National Health and Nutrition Examination Survey. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2813-8
   PubMed Web of Science ®Google Scholar
• Ahmed W, Khan N, Glueck CJ, Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009;153:11-6
   PubMed Web of Science ®Google Scholar
• Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Simvastatin does not affect vitamin D status, but low vitamin D levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol 2010. (In press)
   PubMedGoogle Scholar
• Athyros VG, Papageorgiou AA, Symeonidis AN, ; GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003;54:679-90
   PubMed Web of Science ®Google Scholar
• Shepherd J, Barter P, Carmena R, Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. The Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279-99
   PubMed Web of Science ®Google Scholar
• Jinnouchi Y, Yamagishi S, Takeuchi M, Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006;6:191-3
   PubMed Web of Science ®Google Scholar
• De Cesare D, Di Francesco A, Muraro R, Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006;26:2716-23
   PubMedGoogle Scholar
• Calkin AC, Giunti S, Sheehy KJ, The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 2008;51:1731-40
   PubMed Web of Science ®Google Scholar
• Tam HL, Shiu SWM, Wong Y, Effects of atorvastatin on serum soluble receptors for advanced glycation end\-products in type 2 diabetes. Atherosclerosis 2009. (In press)
   Google Scholar
• Lanting LC, Joung IM, Mackenbach JP, Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients. Diabetes Care 2005;28:2280-8
   PubMed Web of Science ®Google Scholar
• Mainous AG III, Baker R, Koopman RJ, Impact of the population at risk of diabetes on projections of diabetes burden in the Unites States: an epidemic on the way. Diabetologica 2007;50:934-40
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Weerasinghe CN, Mikhailidis DP, Seifalian AM. Vascular risk factors in South Asians. Int J Cardiol 2008;128:5-16
   PubMed Web of Science ®Google Scholar
• The Information Centre for Health and Social Care. Statistics and data collection. Available from: http://www.ic.nhs.uk/statistics-and-data-collections/health-and-lifestyles-related-surveys/health-survey-for-england/health-survey-for-england/ 2004:-health-of-ethnic-minorities-full-report. [Last accessed 4 March 2010]
   Google Scholar
• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31
   PubMed Web of Science ®Google Scholar
• Yoon KH, Lee JH, Kim JW, Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-8
   PubMed Web of Science ®Google Scholar
• Cockram CS. Diabetes mellitus: perspective from the Asia-Pacific region. Diabetes Res Clin Pract 2000;50(Suppl 2):S3-7
   PubMedGoogle Scholar
• Fazio S, Guyton JR, Polis AB, Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol 2010;105:487-94
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Mikhailidis DP. Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009;5:16-7
   PubMedGoogle Scholar
• The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008;83:470-8
   PubMed Web of Science ®Google Scholar
• Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 2007;18:415-20
   PubMed Web of Science ®Google Scholar
• Christie M, Ballantyne CM, Davidson MH, Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non–HDL cholesterol (from the SEACOAST I Study). Am J Cardiol 2008;101:1428-36
   PubMedGoogle Scholar
• Libby A, Meier J, Lopez J, The effect of body mass index on fasting blood glucose and development of diabetes mellitus after initiation of extended-release niacin. Metab Syndr Relat Disord 2010;8:79-84
   PubMed Web of Science ®Google Scholar
• Sharma M, Sharma DR, Singh V, Evaluation of efficacy and safety of fixed dose lovastatin and niacin (ER) combination in Asian Indian dyslipidemic patients: a multicentric study. Vasc Health Risk Manag 2006;2:87-93
   PubMedGoogle Scholar